phosphorus has been researched along with risedronic acid in 11 studies
| Studies (phosphorus) | Trials (phosphorus) | Recent Studies (post-2010) (phosphorus) | Studies (risedronic acid) | Trials (risedronic acid) | Recent Studies (post-2010) (risedronic acid) |
|---|---|---|---|---|---|
| 48,074 | 1,126 | 17,139 | 1,318 | 290 | 487 |
| Protein | Taxonomy | phosphorus (IC50) | risedronic acid (IC50) |
|---|---|---|---|
| Farnesyl pyrophosphate synthase | Homo sapiens (human) | 0.1104 | |
| Farnesyl pyrophosphate synthase | Leishmania donovani | 0.1699 | |
| Farnesyl diphosphate synthase | Toxoplasma gondii | 0.074 | |
| Farnesyl diphosphate synthase | Trypanosoma cruzi | 0.027 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Bekker, PJ; Clemens, TL; Eusebio, RA; Singer, FR | 1 |
| Iwaniec, UT; Mitova-Caneva, NG; Mosekilde, L; Thomsen, JS; Wronski, TJ | 1 |
| Hiraoka, BY; Horiuchi, H; Kobayashi, Y; Matsuura, S; Miyazawa, H; Mogi, M; Nakamura, H; Nakamura, M; Ozawa, H; Saito, N; Takahashi, N; Takaoka, K; Udagawa, N | 1 |
| Barton, IP; Boonen, S; Burgio, DE; Dunlap, LE; Miller, PD; Roux, C | 1 |
| Iwamoto, J; Sato, Y; Seki, A; Shen, CL; Takeda, T; Yamada, H; Yeh, JK | 1 |
| Iwamoto, J; Sato, Y; Seki, A; Takeda, T; Yamada, H; Yeh, JK | 1 |
| Akçay, A; Bavbek, N; Inegöl, I; Kanbay, M; Turgut, FH; Uz, E; Yanik, B; Yanik, T | 1 |
| Atkinson, EJ; Gössl, M; Kane, TL; Khosla, S; Lerman, A; McCready, LK; McGregor, UI; Peris, P | 1 |
| Inoue, D; Maehara, M; Nishizawa, Y; Oikawa, I; Shigematsu, T; Sugimoto, T | 1 |
| Iba, K; Sonoda, T; Takada, J; Yamashita, T | 1 |
| Fukagawa, M; Hamano, N; Ishida, H; Komaba, H; Nakamura, M; Sawada, K; Wada, T; Yamato, H | 1 |
1 review(s) available for phosphorus and risedronic acid
| Article | Year |
|---|---|
Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
Topics: Age Factors; Aged; Aged, 80 and over; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium; Clinical Trials, Phase III as Topic; Creatine; Double-Blind Method; Etidronic Acid; Female; Humans; Kidney Function Tests; Osteoporosis, Postmenopausal; Phosphorus; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Retrospective Studies; Risedronic Acid; Treatment Outcome; Urinary Tract Infections | 2005 |
3 trial(s) available for phosphorus and risedronic acid
| Article | Year |
|---|---|
The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; C-Reactive Protein; Calcium; Etidronic Acid; Female; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Osteoporosis, Postmenopausal; Phosphorus; Raloxifene Hydrochloride; Risedronic Acid; Uric Acid | 2007 |
Effects of bisphosphonate treatment on circulating osteogenic endothelial progenitor cells in postmenopausal women.
Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium; Creatinine; Double-Blind Method; Down-Regulation; Endothelium; Enzyme-Linked Immunosorbent Assay; Etidronic Acid; Female; Flow Cytometry; Gene Expression Regulation; Humans; Interleukin-8; Middle Aged; Osteoblasts; Osteogenesis; Osteoporosis, Postmenopausal; Osteoprotegerin; Phosphorus; Placebos; RANK Ligand; Risedronic Acid; Stem Cells; Treatment Outcome; Vitamin D | 2013 |
Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan.
Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium; Creatinine; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Phosphorus; Renal Insufficiency, Chronic; Risedronic Acid; Treatment Outcome | 2019 |
7 other study(ies) available for phosphorus and risedronic acid
| Article | Year |
|---|---|
Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Calcitriol; Calcium; Calcium Channel Blockers; Creatinine; Etidronic Acid; Female; Humans; Hydroxyproline; Male; Middle Aged; Osteitis Deformans; Parathyroid Hormone; Phosphorus; Risedronic Acid | 1998 |
Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats.
Topics: Aging; Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcium; Drug Synergism; Estrogens; Etidronic Acid; Female; Fibroblast Growth Factor 2; Organ Size; Ovariectomy; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley; Risedronic Acid; Spine | 2002 |
Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption.
Topics: Animals; Bone and Bones; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Bone Resorption; Calcium; Calcium Channel Blockers; Carrier Proteins; Etidronic Acid; Glycoproteins; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Osteocalcin; Osteogenesis; Osteoprotegerin; Phosphorus; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Risedronic Acid; Transforming Growth Factor beta | 2003 |
Comparative effects of risedronate and calcitriol on cancellous bone in rats with glucocorticoid-induced osteopenia.
Topics: Animals; Biomechanical Phenomena; Body Weight; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Bone Resorption; Calcitriol; Calcium; Etidronic Acid; Female; Femur; Phosphorus; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tibia; Tomography, X-Ray Computed | 2006 |
Effect of risedronate on the cortical and cancellous bone mass and mechanical properties in ovariectomized rats: a comparison with the effects of alfacalcidol.
Topics: Analysis of Variance; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Dose-Response Relationship, Drug; Etidronic Acid; Female; Femur; Hydroxycholecalciferols; Ovariectomy; Phosphorus; Random Allocation; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stress, Mechanical; Tibia | 2006 |
Effect of continuous long-term treatment for 10 years with bisphosphonate on Japanese osteoporosis patients.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Asian People; Bone Density; Calcium; Collagen Type I; Diphosphonates; Female; Humans; Japan; Osteoporosis; Osteoporosis, Postmenopausal; Peptides; Phosphorus; Retrospective Studies; Risedronic Acid; Tartrate-Resistant Acid Phosphatase; Time Factors; Treatment Outcome | 2020 |
Skeletal and mineral metabolic effects of risedronate in a rat model of high-turnover renal osteodystrophy.
Topics: Animals; Biomechanical Phenomena; Blood Urea Nitrogen; Bone and Bones; Bone Remodeling; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Creatinine; Disease Models, Animal; Fibroblast Growth Factor-23; Gene Expression Regulation; Humans; Male; Minerals; Nephrectomy; Peptide Fragments; Phosphorus; Procollagen; Rats, Sprague-Dawley; Risedronic Acid | 2020 |